Vascular Dysfunction and Antiangiogenic Therapy — DYVA-AAGG  

Solid Tumor Clinical Trial

Official title: Micro and Macro Vascular Dysfunction Induced by Antiangiogenic Therapy: Identification of New Vascular Biomarkers (DYVA-AAGG)

Status Completed

Clinical Trial Summary

project is a pilot prospective, longitudinal, before-after, open label multicentric study.

Clinical Trial Description

Antiangiogenic drugs and tyrosine kinase inhibitor (TKI) represent a new therapeutic issue in the treatment of several neoplasic tumors (colon, kidney, breast, lung, skin) and hemopathy. Antiangiogenic drugs acts through neutralization of the activity (e.g. bevacizumab) or the inhibition of post-receptor tyrosine kinase pathways (e.g. sunatinib, sorafenib), leading to a reduction and inhibition of the tumoral tissular neovascularization. Due to the ubiquitous role of and the systemic administration of the antiangiogenic drugs, almost all of them are responsible for several side effects, many involving the cardiovascular system (e.g. arterial hypertension, cardiomyopathies, proteinuria, bleedings,...) and leading to a reduction of the doses or withdrawal of the treatment. To date, the mechanism and the impact of these cardiovascular effects is not well understood involving structural (i.e. capillary rarefaction) and functional vascular dysfunction (i.e. vasomotor dysfunction, stiffening). ;

Related Conditions & MeSH terms

• CML (Chronic Myelogenous Leukemia)
• Endothelial Dysfunction
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Solid Tumor
• Tumor Angiogenesis

• NCT number: NCT02161978
• Study type: Observational
• Source: University Hospital, Angers
• Status: Completed
• Start date: February 9, 2012
• Completion date: December 12, 2018